RIBOMIC Advances Pediatric Achondroplasia Treatment Study

Ribomic, Inc. (JP:4591) has released an update.

RIBOMIC Inc., a biopharmaceutical firm, has completed enrollment for its early Phase II study of umedaptanib pegol, a potential treatment for Achondroplasia in children. The study, which involves dosing cohorts at varying levels, aims to assess the efficacy and safety of the drug, with no safety concerns reported to date. The company remains on track with its full-year earnings guidance previously announced.

For further insights into JP:4591 stock, check out TipRanks’ Stock Analysis page.